Saturday 17 October 2026 Export BDSX’s income statement to Excel — free account

Biodesix, Inc.

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.66 1.05 −4.25%

Follow BDSX

Alert me

Market cap: $260.7M
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 4/9
Altman Z: −7.46
Beneish M: −3.13
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.12

Total sells 0.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	2	—	—	—	—	—	—	2	—	—
Sell	5	—	5	10	—	—	—	—	—	—	—	—

Insider Ownership 54.45%

Capital & Financial Ratios $m

Market Cap 260.72

Revenue 102.94

Net Income (27.76)

Free Cash Flow (20.40)

Net Debt 16.82

Current Ratio 2.85

Debt/Equity 5.12

P/E ratio 0.00

Fwd P/E (5.12)

P/S ratio 2.37

P/B ratio 26.64

Past 5Y EPS Growth —

This Y EPS Growth 42.77%

Next Y EPS Growth 37.57%

Next Y revenue growth 26.56%

Next 5Y EPS Growth 39.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 53.57%

10-year low 10-year high

P/B against its own 10 years 82.90%

10-year low 10-year high

EV/Sales against its own 10 years 58.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	26	19	30
Receivables	8	9	9	9
Inventory	—	—	—	—
Other	6	5	4	4
	40	39	33	44

	2023	2024	2025	Q'26
Payables	3	2	3	2
ST’ Debt	0	0	0	—
Other	22	1	1	1
	33	14	17	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	14.20%	32.31%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	26	27	—	—	—
’25	18	20	22	29	88
’24	15	18	18	20	71
’23	9	12	13	15	49
’22	7	11	11	10	38
’21	29	12	7	7	55
’20	5	4	9	27	46

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(2)	—	—	—
’25	(9)	(7)	(9)	1	(23)
’24	(15)	(19)	(11)	(4)	(49)
’23	(8)	1	(4)	(12)	(23)
’22	(13)	(10)	(10)	(12)	(45)
’21	(11)	1	(8)	(10)	(28)
’20	(5)	(4)	(4)	(9)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(2)	—	—	—
’25	(9)	(7)	(9)	1	(24)
’24	(16)	(21)	(11)	(5)	(52)
’23	(15)	(6)	(10)	(15)	(46)
’22	(13)	(10)	(11)	(14)	(49)
’21	(12)	1	(9)	(11)	(31)
’20	(5)	(4)	(5)	(9)	(24)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.81)	(0.71)	—	—	—
’25	(1.60)	(1.60)	(1.16)	(0.49)	(4.67)
’24	(2.80)	(1.60)	(1.40)	(1.20)	(6.60)
’23	(4.80)	(3.40)	(2.80)	(2.00)	(12.80)
’22	(10.00)	(8.00)	(6.80)	(7.00)	(31.00)
’21	(5.20)	(8.20)	(8.20)	(9.80)	(31.60)
’20	(743.68)	(601.16)	(638.60)	(5.00)	(129.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	217.00	80.40	19.10	20.60	22.20	3.44	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	420.30	639.80	119.94	50.60	44.20	31.00
People
People	Employees	—	—	—	—	200	218	245	217	273	334
	Revenue/emp, $m	—	—	0.00	0.00	0.23	0.25	0.16	0.23	0.26	0.26
Income, $m
Income, $m	Revenue	—	—	20	25	46	55	38	49	71	88
	Gross margin, %	—	—	78.44	75.26	51.71	44.01	62.96	73.50	78.17	81.11
	EBT	—	—	(26)	(31)	(31)	(43)	(65)	(52)	(43)	(35)
	EBT margin, %	—	—	(128.06)	(125.15)	(68.81)	(79.18)	(171.27)	(106.23)	(60.19)	(39.85)
	Net income	—	0	(26)	(31)	(31)	(43)	(65)	(52)	(43)	(35)
	Depreciation	—	—	2	3	9	6	11	11	8	7
Per share, $
Per share, $	Revenue	—	—	0.77	2,029.09	188.33	39.83	18.15	11.96	11.02	11.72
	Earnings	—	—	(0.99)	(2,539.34)	(129.60)	(31.60)	(31.00)	(12.80)	(6.60)	(4.67)
	Cash flow	—	—	(0.67)	(1,795.54)	(88.33)	(20.63)	(21.36)	(5.57)	(7.52)	(3.08)
	Capex	—	—	0.00	(117.02)	(9.00)	(1.86)	(1.68)	(5.62)	(0.53)	(0.05)
	Free cash flow	—	—	(0.67)	(1,912.56)	(97.33)	(22.49)	(23.04)	(11.19)	(8.05)	(3.14)
	Book value	—	—	(7.46)	(18,606.53)	170.18	14.42	9.79	1.12	3.23	(0.33)
	Shares, m	—	—	27	0	0	1	2	4	6	8
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.13	0.13	2.14	2.66	2.26	2.98	2.78	0.58
	P/B	—	—	0.00	0.00	2.37	7.34	4.19	31.91	9.48	0.00
	EV/Sales	—	—	1.92	1.92	1.39	2.24	1.79	3.16	2.92	0.90
	EV/FCF	—	—	(2.50)	(2.50)	(2.68)	(3.97)	(1.41)	(3.38)	(4.00)	(3.37)
Cash, $m
Cash, $m	Operating cash flow	—	—	(18)	(22)	(21)	(28)	(45)	(23)	(49)	(23)
	Capex	—	—	(1)	(1)	(2)	(3)	(4)	(23)	(3)	0
	Free cash flow	—	—	(18)	(23)	(24)	(31)	(49)	(46)	(52)	(24)
Balance, $m
Balance, $m	Working capital	—	—	5	(10)	54	15	30	6	25	15
	Total debt	—	—	23	36	28	10	25	35	36	47
	Net debt	—	—	17	31	(34)	(23)	(18)	9	10	28
	Shareholders’ equity	—	—	(198)	(225)	41	20	21	5	21	(2)
Returns, %
Returns, %	ROA	—	—	(133.99)	(73.08)	(37.75)	(43.78)	(77.45)	(54.32)	(43.73)	(38.18)
	ROIC	—	—	0.00	0.00	(210.60)	0.00	(1,229.75)	(190.38)	(69.42)	(67.00)
	ROE	—	—	12.37	14.52	34.08	(141.75)	(324.53)	(414.09)	(337.30)	(383.09)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
FLGT Fulgent Genetics, Inc.	$587.2M	— (loss-making)	— (loss-making)	+4.38% (above 0%: growing)	n/m	+25.36% (above 0%: growing)	30.07%	(42.25%)	Compare
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
BDSX Biodesix, Inc.	$260.7M	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	+72.75% (above 0%: growing)	82.06%	(20.06%)
XGN Exagen Inc.	$207.4M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)	Compare
BNR Burning Rock Biotech Limited Sponsored ADR	$137.1M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)	Compare
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$100.1M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)	Compare
QUCY Quantum Cyber N.V	$95.1M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
Median of peers	$172.2M	—	—	+7.75%	—	+34.17%	64.20%	(16.88%)

All 52 Diagnostics & Research stocks →

Biodesix, Inc. (BDSX) key facts

Strength: Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.
Biodesix, Inc. (BDSX) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BDSX traded at $23.66, a market capitalization of $260.7 million.
Return on equity was −383.1% and debt-to-equity 5.12.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −7.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.